<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423527</url>
  </required_header>
  <id_info>
    <org_study_id>keppra3</org_study_id>
    <nct_id>NCT00423527</nct_id>
  </id_info>
  <brief_title>Levetiracetam in Central Pain in Multiple Sclerosis(MS)</brief_title>
  <official_title>Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <brief_summary>
    <textblock>
      Multiple sclerosis is often associated with pain. There is no standard treatment of this type
      of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve
      central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled,
      cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period)</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain rated on a 0 to 10 point numeric rating scale</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain subtypes rated on the same scale.</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brush-evoked pain</measure>
    <time_frame>Baseline and end of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pin-prick-evoked pain</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold-evoked pain</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (SF36)</measure>
    <time_frame>Baseline and end of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain related sleep disturbance</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of escape medication</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle spasms as measured on 2 different scales</measure>
    <time_frame>Baseline and end of each treatment period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>Levetiracetam tablets 500 mg, total daily dose 3000 mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ms diagnosis verified

          -  age &gt; 18 years

          -  central pain symptoms for more than 3 months

          -  central pain diagnosis confirmed by neurological examination

          -  adequate anticonceptive treatment for women with child bearing potential

          -  informed consent

          -  baseline pain of more than 4 on numeric rating scale

        Exclusion Criteria:

          -  other cause of pain

          -  previous allergic reaction towards levetiracetam

          -  known adverse drug reaction on levetiracetam

          -  pregnancy

          -  severe disease

          -  inability to follow study protocol

          -  treatment with antidepressants, other anticonvulsants or opioids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren H Sindrup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Odense Unviersity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>December 17, 2009</last_update_submitted>
  <last_update_submitted_qc>December 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Søren H. Sindrup</name_title>
    <organization>Odense University Hospital</organization>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>central pain</keyword>
  <keyword>levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

